Conferencia en Melilla sobre las excavaciones en la tumba del visir Amenhotep Huy, en Luxor (Egipto)

  • A cargo de Julia Melero Pascual, de la Fundación Gaselec, tendrá lugar en el Aula de Mayores (Sala de Grados del Campus de la UGR en Melilla) el lunes, 18 de febrero de 2013, a las 19 horas

Las excavaciones en la tumba del visir Amenhotep Huy, situada en Asasif Sur, Luxor (Egipto), serán objeto de una conferencia que ofrecerá en el Aula de Mayores de Melilla, Julia Melero Pascual, de la Fundación Gaselec, institución melillense que participa en las excavaciones de la Tumba 28 de Asasif, localizada en la necrópolis tebana, en el área de Asasif Sur, que fue construida durante el reinado de Amenhotep III (1387-1348 a C.) de la XVIII dinastía.

En la conferencia, que tendrá lugar en la Sala de Grados del Campus de la UGR en Melilla, el lunes, 18 de febrero de 2013, a las 19 horas, Julia Melero dará cuenta del trabajo que realiza la misión arqueológica española en la excavación que financia la Fundación Gaselec en Luxor. Así, la oradora ofrecerá un breve repaso de la geografía del Antiguo Egipto y de las principales características de su civilización, haciendo hincapié en el ámbito funerario, para explicar a continuación la labor de los arqueólogos y cómo estos reconstruyen la historia a través de los restos materiales que hallan.

La exposición, que será complementada con un “PowerPoint” con imágenes de los trabajos, tendrá una duración de media hora, aproximadamente

Para más información: www.visiramenhotep.com

Contacto: Profesora María José Molina García. Departamento de Didáctica de la Lengua y la Literatura. Universidad de Granada. Campus de Melilla. Tfns: 952 698700, 952 698747 y 618 865492. Correo electrónico: mjose@ugr.es


Conferencia en Melilla sobre las excavaciones en la tumba del visir Amenhotep Huy, en Luxor (Egipto)

  • A cargo de Julia Melero Pascual, de la Fundación Gaselec, tendrá lugar en el Aula de Mayores (Sala de Grados del Campus de la UGR en Melilla) el lunes, 18 de febrero de 2013, a las 19 horas

Las excavaciones en la tumba del visir Amenhotep Huy, situada en Asasif Sur, Luxor (Egipto), serán objeto de una conferencia que ofrecerá en el Aula de Mayores de Melilla, Julia Melero Pascual, de la Fundación Gaselec, institución melillense que participa en las excavaciones de la Tumba 28 de Asasif, localizada en la necrópolis tebana, en el área de Asasif Sur, que fue construida durante el reinado de Amenhotep III (1387-1348 a C.) de la XVIII dinastía.

En la conferencia, que tendrá lugar en la Sala de Grados del Campus de la UGR en Melilla, el lunes, 18 de febrero de 2013, a las 19 horas, Julia Melero dará cuenta del trabajo que realiza la misión arqueológica española en la excavación que financia la Fundación Gaselec en Luxor. Así, la oradora ofrecerá un breve repaso de la geografía del Antiguo Egipto y de las principales características de su civilización, haciendo hincapié en el ámbito funerario, para explicar a continuación la labor de los arqueólogos y cómo estos reconstruyen la historia a través de los restos materiales que hallan.

La exposición, que será complementada con un “PowerPoint” con imágenes de los trabajos, tendrá una duración de media hora, aproximadamente

Para más información: www.visiramenhotep.com

Contacto: Profesora María José Molina García. Departamento de Didáctica de la Lengua y la Literatura. Universidad de Granada. Campus de Melilla. Tfns: 952 698700, 952 698747 y 618 865492. Correo electrónico: mjose@ugr.es


Scientists develop a pioneering technique to effectively treat mucositis

his shows a rat subjected to irradiation (radiotherapy). Credit: University of Granada Investigators at the University of Granada have patented a melatonin gel that is 100% effective against this inflammatory reaction. Ads by Google Rabbit Monoclonal Abs – 10000+ Proteins,Antibodies,cDNA, Best Quality Rabbit Mabs,ELISA Kits – www.SinoBiological.com/Antibody Scientists from the University of Granada have patented a compound made from melatonin that is effective in the treatment and prevention of mucositis, one of the most unpleasant side effects of chemotherapy and radiotherapy in cancer patients. It is an easily applied gel that «is believed to be the first product developed anywhere in the world to combat mucositis», according to investigators from the Biomedical Research Centre in Granada. There is currently no treatment for this problem because its physiopathology is still not understood. Mucositis is an inflammatory reaction that affects the mucous membranes throughout the digestive tract from the mouth to the anus, and is one of the principle adverse effects resulting from chemotherapy, radiotherapy and bone marrow transplants. This problem severely complicates the treatment of cancer as patients frequently have to be admitted to hospital, naso-gastric tubes and opiates must be used and, most seriously, radiotherapy treatment against the cancer is interrupted. On some occasions, the results can be fatal. Radiotherapy and Mucositis. It is estimated that 40% of patients who receive radiotherapy and up to 70% of bone marrow transplant patients will develop mucositis. In patients with cancer of the head and neck, 97% develop this condition to some degree, while 100% of those who receive staged radiotherapy over a prolonged period also suffer from mucositis. At the moment no effective treatment for mucositis exists, which is why the product developed at the University of Granada is of such enormous interest to the medical world and the pharmaceutical industry, given that it could greatly enhance the quality of life of cancer patients. This patented compound is the fruit of more than twenty years of research into the properties of melatonin at the University of Granada, which has shown that mitochondrial damage is present in cases of mucositis. «Melatonin alleviates the inflammatory reaction and protects the mitochondria,´ says Germaine Escames Rosa, the principal author of the study, «and for this reason we think it could be useful for treating mucositis.» The success of the treatment developed at the University of Granada is due to the type of gel used in the pharmaceutical formulation, and the amount of melatonin used. «The oral application of this melatonin gel at a specific concentration, impregnates the mucous membranes and reverses the mitochondrial damage, preventing the appearance of mucositis in 100% of cases.» Any other type of melatonin application, such as different concentrations, would not have the same effect. National Patent Via the University of Granada Research Results Transfer Office, the product has already been patented at national level, and an international patent has also been applied for. In addition, the microbiological and stability tests that are required in order to apply for registration as a health product are currently being undertaken, while the research team are involved in preparing for its launch as a commercial product 

Read more at: http://medicalxpress.com/news/2013-02-scientists-technique-effectively-mucositis.html#jCp

Descargar


Scientists develop a pioneering technique to effectively treat mucositis

his shows a rat subjected to irradiation (radiotherapy). Credit: University of Granada Investigators at the University of Granada have patented a melatonin gel that is 100% effective against this inflammatory reaction. Ads by Google Rabbit Monoclonal Abs – 10000+ Proteins,Antibodies,cDNA, Best Quality Rabbit Mabs,ELISA Kits – www.SinoBiological.com/Antibody Scientists from the University of Granada have patented a compound made from melatonin that is effective in the treatment and prevention of mucositis, one of the most unpleasant side effects of chemotherapy and radiotherapy in cancer patients. It is an easily applied gel that «is believed to be the first product developed anywhere in the world to combat mucositis», according to investigators from the Biomedical Research Centre in Granada. There is currently no treatment for this problem because its physiopathology is still not understood. Mucositis is an inflammatory reaction that affects the mucous membranes throughout the digestive tract from the mouth to the anus, and is one of the principle adverse effects resulting from chemotherapy, radiotherapy and bone marrow transplants. This problem severely complicates the treatment of cancer as patients frequently have to be admitted to hospital, naso-gastric tubes and opiates must be used and, most seriously, radiotherapy treatment against the cancer is interrupted. On some occasions, the results can be fatal. Radiotherapy and Mucositis. It is estimated that 40% of patients who receive radiotherapy and up to 70% of bone marrow transplant patients will develop mucositis. In patients with cancer of the head and neck, 97% develop this condition to some degree, while 100% of those who receive staged radiotherapy over a prolonged period also suffer from mucositis. At the moment no effective treatment for mucositis exists, which is why the product developed at the University of Granada is of such enormous interest to the medical world and the pharmaceutical industry, given that it could greatly enhance the quality of life of cancer patients. This patented compound is the fruit of more than twenty years of research into the properties of melatonin at the University of Granada, which has shown that mitochondrial damage is present in cases of mucositis. «Melatonin alleviates the inflammatory reaction and protects the mitochondria,´ says Germaine Escames Rosa, the principal author of the study, «and for this reason we think it could be useful for treating mucositis.» The success of the treatment developed at the University of Granada is due to the type of gel used in the pharmaceutical formulation, and the amount of melatonin used. «The oral application of this melatonin gel at a specific concentration, impregnates the mucous membranes and reverses the mitochondrial damage, preventing the appearance of mucositis in 100% of cases.» Any other type of melatonin application, such as different concentrations, would not have the same effect. National Patent Via the University of Granada Research Results Transfer Office, the product has already been patented at national level, and an international patent has also been applied for. In addition, the microbiological and stability tests that are required in order to apply for registration as a health product are currently being undertaken, while the research team are involved in preparing for its launch as a commercial product 

Read more at: http://medicalxpress.com/news/2013-02-scientists-technique-effectively-mucositis.html#jCp

Descargar


Scientists develop a pioneering technique to effectively treat mucositis

his shows a rat subjected to irradiation (radiotherapy). Credit: University of Granada Investigators at the University of Granada have patented a melatonin gel that is 100% effective against this inflammatory reaction. Ads by Google Rabbit Monoclonal Abs – 10000+ Proteins,Antibodies,cDNA, Best Quality Rabbit Mabs,ELISA Kits – www.SinoBiological.com/Antibody Scientists from the University of Granada have patented a compound made from melatonin that is effective in the treatment and prevention of mucositis, one of the most unpleasant side effects of chemotherapy and radiotherapy in cancer patients. It is an easily applied gel that «is believed to be the first product developed anywhere in the world to combat mucositis», according to investigators from the Biomedical Research Centre in Granada. There is currently no treatment for this problem because its physiopathology is still not understood. Mucositis is an inflammatory reaction that affects the mucous membranes throughout the digestive tract from the mouth to the anus, and is one of the principle adverse effects resulting from chemotherapy, radiotherapy and bone marrow transplants. This problem severely complicates the treatment of cancer as patients frequently have to be admitted to hospital, naso-gastric tubes and opiates must be used and, most seriously, radiotherapy treatment against the cancer is interrupted. On some occasions, the results can be fatal. Radiotherapy and Mucositis. It is estimated that 40% of patients who receive radiotherapy and up to 70% of bone marrow transplant patients will develop mucositis. In patients with cancer of the head and neck, 97% develop this condition to some degree, while 100% of those who receive staged radiotherapy over a prolonged period also suffer from mucositis. At the moment no effective treatment for mucositis exists, which is why the product developed at the University of Granada is of such enormous interest to the medical world and the pharmaceutical industry, given that it could greatly enhance the quality of life of cancer patients. This patented compound is the fruit of more than twenty years of research into the properties of melatonin at the University of Granada, which has shown that mitochondrial damage is present in cases of mucositis. «Melatonin alleviates the inflammatory reaction and protects the mitochondria,´ says Germaine Escames Rosa, the principal author of the study, «and for this reason we think it could be useful for treating mucositis.» The success of the treatment developed at the University of Granada is due to the type of gel used in the pharmaceutical formulation, and the amount of melatonin used. «The oral application of this melatonin gel at a specific concentration, impregnates the mucous membranes and reverses the mitochondrial damage, preventing the appearance of mucositis in 100% of cases.» Any other type of melatonin application, such as different concentrations, would not have the same effect. National Patent Via the University of Granada Research Results Transfer Office, the product has already been patented at national level, and an international patent has also been applied for. In addition, the microbiological and stability tests that are required in order to apply for registration as a health product are currently being undertaken, while the research team are involved in preparing for its launch as a commercial product 

Read more at: http://medicalxpress.com/news/2013-02-scientists-technique-effectively-mucositis.html#jCp

Descargar


University of Granada’s melatonin gel effective in treating and preventing mucositis

Mucositis is one of the most frequent side effects of chemotherapy and radiotherapy in cancer patients and currently cannot be treated. Investigators at the University of Granada have patented a melatonin gel that is 100% effective against this inflammatory reaction.

Scientists from the University of Granada have patented a compound made from melatonin that is effective in the treatment and prevention of mucositis, one of the most unpleasant side effects of chemotherapy and radiotherapy in cancer patients. It is an easily applied gel that «is believed to be the first product developed anywhere in the world to combat mucositis», according to investigators from the Biomedical Research Centre in Granada. There is currently no treatment for this problem because its physiopathology is still not understood.

Mucositis is an inflammatory reaction that affects the mucous membranes throughout the digestive tract from the mouth to the anus, and is one of the principle adverse effects resulting from chemotherapy, radiotherapy and bone marrow transplants. This problem severely complicates the treatment of cancer as patients frequently have to be admitted to hospital, naso-gastric tubes and opiates must be used and, most seriously, radiotherapy treatment against the cancer is interrupted. On some occasions, the results can be fatal.

Radiotherapy and Mucositis.

It is estimated that 40% of patients who receive radiotherapy and up to 70% of bone marrow transplant patients will develop mucositis. In patients with cancer of the head and neck, 97% develop this condition to some degree, while 100% of those who receive staged radiotherapy over a prolonged period also suffer from mucositis.

At the moment no effective treatment for mucositis exists, which is why the product developed at the University of Granada is of such enormous interest to the medical world and the pharmaceutical industry, given that it could greatly enhance the quality of life of cancer patients.

This patented compound is the fruit of more than twenty years of research into the properties of melatonin at the University of Granada, which has shown that mitochondrial damage is present in cases of mucositis. «Melatonin alleviates the inflammatory reaction and protects the mitochondria,´ says Germaine Escames Rosa, the principal author of the study, «and for this reason we think it could be useful for treating mucositis.»

Descargar


University of Granada’s melatonin gel effective in treating and preventing mucositis

Mucositis is one of the most frequent side effects of chemotherapy and radiotherapy in cancer patients and currently cannot be treated. Investigators at the University of Granada have patented a melatonin gel that is 100% effective against this inflammatory reaction.

Scientists from the University of Granada have patented a compound made from melatonin that is effective in the treatment and prevention of mucositis, one of the most unpleasant side effects of chemotherapy and radiotherapy in cancer patients. It is an easily applied gel that «is believed to be the first product developed anywhere in the world to combat mucositis», according to investigators from the Biomedical Research Centre in Granada. There is currently no treatment for this problem because its physiopathology is still not understood.

Mucositis is an inflammatory reaction that affects the mucous membranes throughout the digestive tract from the mouth to the anus, and is one of the principle adverse effects resulting from chemotherapy, radiotherapy and bone marrow transplants. This problem severely complicates the treatment of cancer as patients frequently have to be admitted to hospital, naso-gastric tubes and opiates must be used and, most seriously, radiotherapy treatment against the cancer is interrupted. On some occasions, the results can be fatal.

Radiotherapy and Mucositis.

It is estimated that 40% of patients who receive radiotherapy and up to 70% of bone marrow transplant patients will develop mucositis. In patients with cancer of the head and neck, 97% develop this condition to some degree, while 100% of those who receive staged radiotherapy over a prolonged period also suffer from mucositis.

At the moment no effective treatment for mucositis exists, which is why the product developed at the University of Granada is of such enormous interest to the medical world and the pharmaceutical industry, given that it could greatly enhance the quality of life of cancer patients.

This patented compound is the fruit of more than twenty years of research into the properties of melatonin at the University of Granada, which has shown that mitochondrial damage is present in cases of mucositis. «Melatonin alleviates the inflammatory reaction and protects the mitochondria,´ says Germaine Escames Rosa, the principal author of the study, «and for this reason we think it could be useful for treating mucositis.»

Descargar


Melilla Hoy

Pág. 17: SATE-STEs organiza un taller para interesados en la alfabetización de adultos

Descarga por URL: http://sl.ugr.es/03sz

Descargar


Melilla Hoy

Pág. 17: SATE-STEs organiza un taller para interesados en la alfabetización de adultos

Descarga por URL: http://sl.ugr.es/03sz

Descargar


El Telegrama de Melilla

Pág. 16: SATE-STEs organiza un año más el Taller de Formadores de Personas Adultas

Descarga por URL: http://sl.ugr.es/03sy

Descargar


El Telegrama de Melilla

Pág. 16: SATE-STEs organiza un año más el Taller de Formadores de Personas Adultas

Descarga por URL: http://sl.ugr.es/03sy

Descargar


El Faro de Melilla

Pág. 19: Los profesores de adultos se forman en igualdad gracias a SATE-STEs

Descarga por URL: http://sl.ugr.es/03sx

Descargar